GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Valuation Rank

MBCOF (Marvel Biosciences) Valuation Rank


View and export this data going back to 2023. Start your Free Trial

What is Marvel Biosciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Marvel Biosciences Valuation Rank Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Marvel Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Valuation Rank
Comparable Companies
XCNQ:ASEP XCNQ:LOBE TSXV:QPT TSX:APLI XCNQ:RIZE TSXV:XRTX TSXV:IOT TSXV:IBO TSXV:CYTO XCNQ:NURL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
MRVL:Canada
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Website
https://www.marvelbiotechnology.com
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.